Manu Vanaerschot Selected Research

Drug Therapy (Chemotherapy)

1/2021	The antimalarial efficacy and mechanism of resistance of the novel chemotype DDD01034957.
1/2017	Macromolecular biosynthetic parameters and metabolic profile in different life stages of Leishmania braziliensis: Amastigotes as a functionally less active stage.
4/2015	Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manu Vanaerschot Research Topics

Disease

9	Visceral Leishmaniasis (Kala Azar) 01/2017 - 10/2010
6	Malaria 01/2022 - 01/2018
2	Parasitemia 12/2018 - 06/2014
2	Infections 12/2018 - 01/2017
2	Reinfection 10/2013 - 06/2013
1	COVID-19 11/2023
1	Aneuploidy (Aneuploid) 01/2020
1	Asymptomatic Infections 01/2017
1	Leishmaniasis 10/2013

Drug/Important Bio-Agent (IBA)

5	Antimalarials (Antimalarial Agents)IBA 01/2021 - 12/2018
3	miltefosine (Impavido)IBA 10/2013 - 06/2013
2	DNA (Deoxyribonucleic Acid)IBA 11/2023 - 01/2020
2	N(1)-methyl-2-lysergic acid diethylamide (MIL)IBA 10/2013 - 06/2013
1	Acetate-CoA Ligase (Acetyl CoA Synthetase)IBA 01/2022
1	InsecticidesIBA 01/2021
1	alpha-aminopyridineIBA 01/2018
1	MMV390048IBA 01/2018
1	1-Phosphatidylinositol 4-Kinase (1 Phosphatidylinositol 4 Kinase)IBA 01/2018
1	RNA (Ribonucleic Acid)IBA 01/2017
1	Messenger RNA (mRNA)IBA 01/2017
1	Drug CombinationsIBA 04/2015
1	QuinazolinesIBA 06/2014
1	Genetic Markers (Genetic Marker)IBA 09/2012
1	AntimonyIBA 01/2012
1	18S Ribosomal RNAIBA 10/2010

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 01/2021 - 04/2015
2	Therapeutics 01/2021 - 06/2013
1	Aftercare (After-Treatment) 10/2013